Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Cybin Receives FDA Clearance for Phase 1/2a Trial
“We are extremely pleased to advance CYB003 into clinical development so quickly. Our team has worked diligently to achieve this major regulatory milestone and we look forward to collaborating with Clinilabs, our drug development partner, to accelerate this program,” said Doug Drysdale, Chief Executive Officer of Cybin. “This Phase 1/2a trial represents the first time that a psilocybin analog will be evaluated for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering with mental health conditions.”
KPMG Releases Positive Report on Psychedelics
KPMG putting out a report on psychedelics was low-key big news. KPMG is a major multinational professional services network and one of the “Big Four” accounting organizations, so a positive report on the industry, even a relatively small one, can go a long way in legitimizing the space in the eyes of more conservative institutional investors.
Michael Pollan Psychedelics Documentary to Launch on Netflix
The acclaimed journalist and author is known for in-depth and accessible long-form that brings readers deep into an eclectic array of topics, often personally experiencing the subject matter first hand. Pollan’s most recent book was How To Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence, a very experiential deep dive into the world of psychedelics.
We now have the announcement of a How to Change Your Mind documentary coming to Netflix in July 2022, a piece of news that should go a long way in further bringing psychedelics out from the shadows and into mainstream acceptance.
Numinus Unveils New Logo and Brand Identity
The rebranding will be completed in a multi-phased approach, with current Numinus branded assets and websites immediately being rebranded, followed by the rebranding of subsidiaries Mindspace, the Neurology Centre of Toronto, Cedar Psychiatry, Cedar Clinical Research and Foundations for Change later in the year. Numinus expects all assets to be rebranded to showcase one unified brand by the end of 2022.
FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
The trial is funded by a $4 million grant from the National Institutes of Health, the first time in 50 years the U.S. government has funded a study of psychedelics. The Investigator Initiated trial is funded by a near $4 million grant from the National Institutes of Health, making this the first time in 50 years the U.S. government has funded a study evaluating a psychedelic compound for therapeutic use. The randomized trial aims to determine if psilocybin increases smoking abstinence compared to a placebo, both paired with cognitive-behavioral therapy (CBT).
